Patents by Inventor Nicholas Michael Kelly

Nicholas Michael Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stabilization of amyloidogenic immunoglobulin light chains
    Patent number: 11945806
    Abstract: In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL patients, such as those with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, provided herein are small molecule compounds of Formula Ia, Formula Ib, and Formula II that are kinetic stabilizers of the native dimeric structure of full-length LCs, which compounds can slow or stop the amyloidogenicity cascade at its origin.
    Type: Grant
    Filed: March 29, 2020
    Date of Patent: April 2, 2024
    Inventors: Jeffery W. Kelly, Gareth John Morgan, Nicholas Lok Yan, Hank Michael James Petrassi
  • Animal feed compositions and uses thereof
    Patent number: 10959942
    Abstract: The present invention relates to animal feed compositions comprising polypeptides having lysozyme activity and polypeptides having phytase activity and uses thereof.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: March 30, 2021
    Inventors: Dorthe Hoej Sandvang, Esben Gad, Nicholas Michael Kelly, Mikkel Klausen, Juliane Charlotte Gregaard Thoegersen, Peter Bjarke Olsen, Preben Nielsen, Marianne Thorup Cohn
  • Animal Feed Compositions and Uses Thereof
    Publication number: 20180296475
    Abstract: The present invention relates to animal feed compositions comprising polypeptides having lysozyme activity and polypeptides having phytase activity and uses thereof.
    Type: Application
    Filed: July 4, 2016
    Publication date: October 18, 2018
    Applicants: Novozymes A/S, DSM IP Assets B.V.
    Inventors: Dorthe Hoej Sandvang, Esben Gad, Nicholas Michael Kelly, Mikkel Klausen, Juliane Charlotte Gregaard Thoegersen, Peter Bjarke Olsen, Preben Nielsen, Marianne Thorup Cohn
  • BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS
    Publication number: 20100216840
    Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
    Type: Application
    Filed: May 7, 2010
    Publication date: August 26, 2010
    Applicant: ACADIA PHARMACEUTICALS INC.
    Inventors: NICHOLAS MICHAEL KELLY, KRISTIAN NORUP KOCH, BO-RAGNAR TOLF
  • Benzimidazolidinone derivatives as muscarinic agents
    Patent number: 7300928
    Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: November 27, 2007
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
  • Benzimidazolidinone derivatives as muscarinic agents
    Patent number: 7291611
    Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: November 6, 2007
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
  • Benzimidazolidinone derivatives as muscarinic agents
    Patent number: 7273857
    Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: September 25, 2007
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
  • Benzimidazolidinone derivatives as muscarinic agents
    Patent number: 7087593
    Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: August 8, 2006
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
  • Benzimidazolidinone derivatives as muscarinic agents
    Patent number: 6951849
    Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: October 4, 2005
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
  • Benzimidazolidinone derivatives as muscarinic agents
    Publication number: 20040067931
    Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
    Type: Application
    Filed: April 3, 2003
    Publication date: April 8, 2004
    Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
  • Benzimidazolidinone derivatives as muscarinic agents
    Publication number: 20030100545
    Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
    Type: Application
    Filed: September 30, 2002
    Publication date: May 29, 2003
    Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf